Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €13.21 EUR
Change Today -1.13 / -7.86%
Volume 0.0
GBY On Other Exchanges
Symbol
Exchange
GBY is not on other exchanges.
As of 3:11 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

sangamo biosciences inc (GBY) Snapshot

Open
€14.27
Previous Close
€14.34
Day High
€14.43
Day Low
€13.14
52 Week High
03/20/15 - €17.75
52 Week Low
10/13/14 - €7.41
Market Cap
913.7M
Average Volume 10 Days
1.0K
EPS TTM
--
Shares Outstanding
69.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANGAMO BIOSCIENCES INC (GBY)

sangamo biosciences inc (GBY) Related Businessweek News

No Related Businessweek News Found

sangamo biosciences inc (GBY) Details

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States. Its zinc finger DNA-binding proteins (ZFPs) could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways for genome editing and gene regulation; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The company’s principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimer’s disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntington’s disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.

102 Employees
Last Reported Date: 02/25/15
Founded in 1995

sangamo biosciences inc (GBY) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $640.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.0K
Chief Medical Officer and Vice President of T...
Total Annual Compensation: $437.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $385.0K
Executive Vice President of Research and Deve...
Total Annual Compensation: $453.5K
Compensation as of Fiscal Year 2013.

sangamo biosciences inc (GBY) Key Developments

Sangamo Biosciences Inc. Announces Encouraging Data from Phase I/II HIV Trial

Sangamo Biosciences Inc. has announced encouraging clinical data from a Phase I/II clinical trial with its ZFP therapeutic, SB-728-T, in patients with HIV infection. The study is designed to evaluate SB-728-T, a ZFP Therapeutic generated by ZFN-mediated genome editing of T-cells to knockout the CCR5 gene, which encodes a critical co-receptor for HIV infection. SB-728-T is being developed as a potential 'functional cure' for HIV/AIDS. The 1101 study was designed to evaluate the effect of increasing doses of Cytoxan preconditioning as a method to maximize engraftment of ZFN- modified cells (SB-728-T) in which both copies of the CCR5 gene had been disrupted, making the cells fully resistant to HIV infection. Data from Cohorts 1-5 of the 1101 study (18 subjects) demonstrated a dose-related increase in both total CD4 T-cell and ZFN modified CD4 T-cell engraftment in response to Cytoxan preconditioning up to 1.0 g/m2. In addition, all subjects underwent a TI and were taken off ART at sixteen weeks post infusion. Four subjects from Cohort 1-5 remain on long-term TI and have remained off ART for at least 40 weeks. New data reported at CROI also included a further cohort (3) of three subjects who received a ZFN-mediated CCR5 modified SB-728-T product containing both CD4 and CD8 T-cells. Among the three subjects treated in Cohort 3, one displayed a reduction in viral load below the limit of quantification (LOQ). Another subject displayed a markedly delayed onset of viremia for over 8 weeks from the start of TI. TI is ongoing in all three subjects. CD8 cells are the cells that are directly involved in clearance of the virus with 'help' from CD4 cells. 'Elite controllers' have been shown to have elevated levels of CD8 T-cells that express low levels of CCR5 and have good anti-viral responses.

Sangamo BioSciences Presents New Clinical Data at CROI 2015 From Trial of ZFP Therapeutic® Designed to Provide Functional Control of HIV

Sangamo BioSciences Inc. announced the presentation of new clinical data from its Phase 1/2 clinical trial (SB-728-1101). The study is designed to evaluate SB-728-T, a ZFP Therapeutic® generated by ZFN-mediated genome editing of T-cells to knockout the CCR5 gene, which encodes a critical co-receptor for HIV infection. SB-728-T is being developed as a potential 'functional cure' for HIV/AIDS. The data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) which is being held in Seattle from February 23 to 26, 2015. The 1101 study was designed to evaluate the effect of increasing doses of Cytoxan® preconditioning as a method to maximize engraftment of ZFN- modified cells (SB-728-T) in which both copies of the CCR5 gene had been disrupted, making the cells fully resistant to HIV infection. Data from Cohorts 1-5 of the 1101 study (18 subjects) demonstrated a dose-related increase in both total CD4 T-cell and ZFN modified CD4 T-cell engraftment in response to Cytoxan preconditioning up to 1.0 g/m2. In addition, all subjects underwent a TI and were taken off ART at sixteen weeks post infusion. Four subjects from Cohort 1-5 remain on long-term TI and have remained off ART for at least 40 weeks. New data reported at CROI also included a further cohort of three subjects who received a ZFN-mediated CCR5 modified SB-728-T product containing both CD4 and CD8 T-cells. Among the three subjects treated in Cohort 3, one displayed a reduction in viral load below the limit of quantification (LOQ). Another subject displayed a markedly delayed onset of viremia for over 8 weeks from the start of TI. TI is ongoing in all three subjects. CD8 cells are the cells that are directly involved in clearance of the virus with "help" from CD4 cells. 'Elite controllers' have been shown to have elevated levels of CD8 T-cells that express low levels of CCR5 and have good anti-viral responses, a characteristic shared by those SB-728-T treated subjects in which the effects on the virus have been seen to date. Sangamo has an ongoing Phase 2 clinical trial, SB-728-mR-1401, designed to provide further evidence of functional control of HIV in additional subjects. The protocol incorporates a number of methods to increase the engraftment of CD4 T-cells that have undergone biallelic CCR5 gene modification, including certain criteria for subject selection, Cytoxan preconditioning and a number of process improvements such as mRNA delivery of the ZFNs, which will allow the administration of multiple doses. The Company completed patient accrual for this study in 2014 and expects to report preliminary data by the end of 2015. HIV-infected subjects were enrolled in a Phase 1/2 clinical trial (SB-728-1101) in six cohorts. Cohorts 1-5, (18 subjects) designed primarily to evaluate the safety and tolerability of escalating doses of cyclophosphamide (Cytoxan®) (doses tested: 200 mg, 500 mg/m2, 1.0g/m2, 1.5g/m2 or 2.0g/m2) administered prior to an infusion of SB-728-T (CD4 cell enriched). The sixth cohort, Cohort 3, (3 subjects) was designed to evaluate a CD4/CD8 SB-728-T product post-administration of Cytoxan at the optimal dose of 1.0g/m2. Cytoxan is a drug that is used to transiently reduce the numbers of T-cells in the body, which then rapidly repopulate once the drug is discontinued, and it is into this "growth" environment that SB-728-T is infused. Such lymphodepletive treatment has been used to enhance engraftment of adoptively transferred T-cells in the treatment of cancer, and as therapy for numerous autoimmune diseases. All subjects were on ART and had stably controlled undetectable levels of HIV in their blood. Each subject received a single dose of SB-728-T (8 to 36 billion cells) after a dose of Cytoxan. The study evaluated safety and tolerability of escalating doses of Cytoxan preconditioning, changes in CD4+ T-cell counts and the ratio of CD4+ to CD8+ T-cells, as well as levels of SB-728-T in the blood and levels of viral load during a 16 week TI beginning six weeks after subjects received the SB-728-T treatment. Analysis of the data from subjects in the study presented, demonstrated: Cytoxan preconditioning at doses up to 1.0 gm/m2 safely enhanced total CD4 and CCR5 modified CD4 T-cells (Cohorts 1-5, 18 subjects); four subjects who received either 1.0 or 1.5 gm/m2 remain on long-term TI, (40-71 weeks); CD8 repletion in Cohort 3 did not affect the safety profile of SB-728-T; in Cohort 3 increased levels of CCR5 modified CD8 T-cells were observed post infusion, suggesting expansion of CD8 T-cells; three subjects from Cohort 3 have shown a doubling of their CD8 T-cells, with one subject displaying control of viral load below the LOQ during TI, and another displaying delayed onset of viremia during TI.

Sangamo Biosciences Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the Full Year of 2015

Sangamo Biosciences Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $14,952,000 against $6,869,000 a year ago. Loss from operations was $4,469,000 against $8,174,000 a year ago. Net loss was $4,319,000 or $0.06 per basic and diluted share against $8,144,000 or $0.13 per basic and diluted share a year ago. Fourth quarter 2014 revenues were generated from the company's collaboration agreements with Shire International GmbH (Shire), Biogen Idec (Biogen), Dow AgroSciences, and Sigma Aldrich, enabling technology agreements and research grants. Net cash used in operating activities was $2.9 million for the fourth quarter. For the year, the company reported total revenues of $45,870,000 against $24,133,000 a year ago. Loss from operations was $26,781,000 against $26,706,000 a year ago. Net loss was $26,417,000 or $0.39 per basic and diluted share against $26,624,000 or $0.48 per basic and diluted share a year ago. Net cash used in operating activities was $5.8 million. For the year of 2015, the company expects revenues in the range of $60 million to $70 million, inclusive of research funding and certain milestone payments from Shire and Biogen.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GBY:GR €13.21 EUR -1.13

GBY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bluebird Bio Inc $132.51 USD -1.42
Fibrocell Science Inc $4.00 USD -0.03
View Industry Companies
 

Industry Analysis

GBY

Industry Average

Valuation GBY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.7x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGAMO BIOSCIENCES INC, please visit www.sangamo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.